Advancing detection and monitoring of drug-resistance tuberculosis with next-generation sequencing (NGS)

Tuberculosis (TB) is a leading cause of death from infectious disease and is very difficult to control due to multiple drug resistances. Rapid identification of TB and its drug resistance profile is critical for management and surveillance of disease. Current testing options are insufficient due to the length of time for culture-based results or limited drug resistance results from molecular tests.

The Genoscreen Deeplex Myc-TB next-generation sequencing (NGS) assay detects more than 100 mycobacterium species and provides an extensive drug resistance profile for 15 antibiotics commonly used for TB. Results are available in less than 48 hours directly from a sputum sample or cultured isolate. TB detection with drug resistance in an actionable timeframe is a leap forward in managing and monitoring tuberculosis.

At the end of this webinar, attendees will be able to:

• Understand the current tuberculosis landscape and global impact of drug resistance on TB management
• Describe how next-generation sequencing is used to identify, detect and monitor TB drug resistance
• Explain how the Deeplex Myc-TB assay fits into a laboratory workflow

Darcy Whitlock
Sr Staff Product Mgr
Illumina